DRG Market Assessment reports

Stage of disease, resectability of the primary tumor, and BRAF mutation status are key parameters influencing the treatment paradigm of malignant melanoma. BRAF/MEK inhibitor combination regimens,…

KEY BENEFITS AND USES Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting. Drill down into physicians’ treatment sequences and understand which drugs…

Pulmonary hypertension (PH) is a rare and life-threatening disorder marked by considerable morbidity and mortality. Off-label drug use is widespread because drugs have been approved only for the…

Severe allergic rhinitis (AR) is a chronic immunoglobulin E (IgE)-mediated respiratory response to seasonal and/or perennial environmental allergens. Treatment options include intranasal…

Treatments for opioid addiction are categorized as either substitution therapies—the opioid receptor agonists methadone, buprenorphine, and buprenorphine / naloxone combinations—or abstinence…

Essential thrombocythemia (ET) is a hematological malignancy characterized by thrombocytosis. Based on patients’ age and clinical findings, patients can be classified into different categories,…

Galactosemia is a group of inherited metabolic disorders characterized by the body’s inability to produce a sufficient amount of enzymes to process galactose. The mostly commonly insufficient…

Despite the number of therapy options available, advanced or metastatic HR-positive / HER2-negative breast cancer remains incurable and a major cause of mortality and morbidity in women. Later-line…

Seborrheic dermatitis is a chronic inflammatory skin disorder characterized by scaly, erythematous, and itchy skin in sebum-rich areas of the body (e.g., scalp, face, upper chest). The severity of…

Insomnia is a highly prevalent condition with obvious indirect economic costs, but payers may not be fully aware of the healthcare cost savings that could result from ensuring patient access to…

The type 2 diabetes (T2D) drug market is expected to expand, fueled by a rich pipeline of agents. However, growth will be tempered because these emerging therapies will be predominantly later-to-…

OA pain is the second largest segment of the overall chronic pain market, affecting more than 90 million patients in the G7. The OA pain market represents a lucrative opportunity for drug…